So, here goes: one level is no more important than another. A level 3 company is no better than a level 2 – just different. As levels progress numerically, they can get more complex and require more capital; later levels are further away from market than earlier levels, many of which are already in-market and making revenue.

Level 4 is the new community of longevity clinics and doctors employing professional diagnostics for health and aging biomarkers, offering clinical guidance on lifestyle, diet and therapeutic interventions to mitigate the progression of age. For many, this is the key gateway for the development of the whole industry.

Level 5 is basically the current aging disease management layer, which is pretty much the current healthcare (sick-care) industry humans have been aligned with for millennia.

Level 7 is where it starts to get very longevity-specific: therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases. These therapies may well have additional ‘overspill’ benefits for other organs/hallmarks.

Level 8 is where we all want to be: therapeutic interventions that stop or reverse age-related damage throughout the whole-body system. Levels 9 and 10 are the placeholders for ‘staying in the game’ while the great research and development work in the longevity field continues along multiple pathways of funding, regulatory approval, acquisition and commercialization.

Here are the ‘Ten Levels of Longevity’ list in full and the definitions of each level.